EMA Authorised: Tepkinly (epcoritamab) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

The EMA authorised Tepkinly (epcoritamab) from AbbVie Deutschland for diffuse large B-cell lymphoma, with conditional approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Tepkinly (epcoritamab)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Large B-Cell, Diffuse. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 06/02/2026. Conditional approval